ErbB2 overexpression in human breast carcinoma is correlated with p21 Cip1 up-regulation and tyrosine-15 hyperphosphorylation of p34 Cdc2: Poor responsiveness to chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil is associated with ErbB2 overexpression and with p21Cip1 overexpression

Cancer

Volumn 98, Issue 6, 2003, Pages 1123-1130

  Yang, Wentao ^b   Klos, Kristine S ^b   Zhou, Xiaoyan ^b   Yao, Jun ^b   Yang, Ying ^b   Smith, Terry L ^b   Shi, Daren ^b   Yu, Dihua ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b NONE

Author keywords

Breast carcinoma; ErbB2; p21Cip1; p34Cdc2 phosphorylation

Indexed keywords

CYCLOPHOSPHAMIDE; FLUOROURACIL; MESSENGER RNA; METHOTREXATE; PROTEIN KINASE; PROTEIN P21;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG RESPONSE; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MAJOR CLINICAL STUDY; ONCOGENE NEU; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; UPREGULATION;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CDC2 PROTEIN KINASE; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; CYCLOPHOSPHAMIDE; DRUG RESISTANCE, NEOPLASM; FEMALE; FLUOROURACIL; HUMANS; IMMUNOHISTOCHEMISTRY; METHOTREXATE; MIDDLE AGED; PHOSPHORYLATION; RECEPTOR, ERBB-2; RNA, MESSENGER; TYROSINE; UP-REGULATION;

EID: 0042418235     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11625     Document Type: Article

References (46)

1. Sommer S, Fuqua SA. Estrogen receptor and breast cancer. Semin Cancer Biol. 2001;11:339-352.
2. Yu D, Hung MC. Overexpression of ErbB2 in cancer and ErbB2 targeting strategies. Oncogene. 2000;19:6115-6121.
3. Davidoff A, Kerns B, Inglehard J, Marks J. Maintenance of p53 alterations throughout breast cancer progression. Cancer Res. 1991;51:2605-2610.
4. Barnes DM. Cyclin D1 in mammary carcinoma. J Pathol. 1997;181:267-269.
5. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D. p21 is a universal inhibitor of cyclin kinases. Nature. 1993;366:701-704.
6. El-Deiry W, Tokino T, Velculescu VE, et al. Waf1, a potential mediator of p53 tumor suppression. Cell. 1993;75:817-825.
7. Waldman T, Lengauer C, Kinzler KW, Vogelstein B. Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21. Nature. 1996;381:713-716.
8. Dotto GP. p21(WAF1/Cip1): more than a break to the cell cycle? Biochim Biophys Acta. 2000;1471:M43-M56.
9. Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells. Nat Cell Biol. 2001;3:245-252.
10. Thor A, Liu S, Moore DH, Shi Q, Edgerton SM. P21WAF1/CIP1 expression in breast cancers: associations with p53 and outcome. Breast Cancer Res Treat. 2000;61:33-43.
11. Jiang M, Shao ZM, Lu JS, et al. p21/waf1/cip1 and mdm-2 expression in breast carcinoma patients as related to prognosis. Int J Cancer. 1997;74:529-534.
12. Domagala W, Welcker M, Chosia M, et al. p21/WAF1/Cip1 expression in invasive ductal breast carcinoma: relationship to p53, proliferation rate, and survival at 5 years. Virchows Arch. 2001;439:132-140.
13. Gohring UJ, Bersch A, Becker M, Neuhaus W, Schondorf T. p21(waf) correlates with DNA replication but not with prognosis in invasive breast cancer. J Clin Pathol. 2001;54:866-870.
14. Megha T, Lazzi S, Ferrari F, et al. Expression of the G2-M checkpoint regulators cyclin B1 and P34CDC2 in breast cancer: a correlation with cellular kinetics. Anticancer Res. 1999;19:163-169.
15. cdc2. Cell. 1990;63:1013-1024.
16. Irniger S, Piatti S, Michaelis C, Nasmyth K. Genes involved in sister chromatid separation are needed for B-type cyclin proteolysis in budding yeast. Cell. 1995;81:269-277.
17. MO15. EMBO J. 1993;12:3133-3142.
18. cdc2. EMBO J. 1993;12:3123-3132.
19. Fesquet D, Labbe JC, Derancourt J, et al. The MO15 gene encodes the catalytic subunit of a protein kinase that activates cdc2 and other cyclin-dependent kinases (CDKS) through phosphorylation of Thr161 and its homologues. EMBO J. 1993;12:3111-3121.
20. Russell P, Nurse P. Negative regulation of mitosis by weel +, a gene encoding a protein kinase homolog. Cell. 1987;49:559-567.
21. cdc2 on threonine 14. Mol Biol Cell. 1994;5:273-282.
22. Smythe C, Newport J. Coupling of mitosis to the completion of S phase in Xenopus occurs via modulation of the tyrosine kinase that phosphorylates p34cdc2. Cell. 1992;68:787-797.
23. Dunphy WG, Kumagai A. The cdc25 protein contains an intrinsic phosphatase activity. Cell. 1991;67:189-196.
24. Meikrantz W, Schlegel R. Suppression of apoptosis by dominant negative mutants of cyclin-dependent protein kinases. J Biol Chem. 1996;271:10205-10209.
25. Cdc2 kinase. Mol Cell. 1998;2:581-591.
26. Dulic V, Stein GH, Far DF, Reed SI. Nuclear accumulation of p21cip1 at the onset of mitosis: a role at the g2/M-phase transition. Mol Cell Biol. 1998;18:546-557.
27. 2/M cell cycle transitions: pRb is a critical determinant in blocking DNA replication and in preventing endoreduplication. Mol Cell Biol. 1998;18:629-643.
28. Tan M, Jing T, Lan KH, et al. Phosphorylation on tyrosine-15 of p34(Cdc2) by ErbB2 inhibits p34(Cdc2) activation and is involved in resistance to taxol-induced apoptosis. Mol Cell. 2002;9:993-1004.
29. Kawamoto H, Koizumi H, Uchikoshi T. Expression of the G2-M checkpoint regulators cyclin B1 and cdc2 in nonmalignant and malignant human breast lesions: immunocytochemical and quantitative image analyses. Am J Pathol. 1997;150:15-23.
30. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244:707-712.
31. Gusterson BA, Gelber RD, Goldhirsch A, et al. Prognostic importance of c-erbB-2 expression in breast cancer. J Clin Oncol. 1992;10:1049-1056.
32. Paik S, Hazan R, Fisher ER, et al. Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer. J Clin Oncol. 1990;8:103-112.
33. Rilke F, Colnaghi MI, Cascinelli N, et al. Prognostic significance of HER-2/neu expression in breast cancer and its relationship to other prognostic factors. Int J Cancer. 1991;49:44-49.
34. Wright C, Angus B, Nicholson S, et al. Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer. Cancer Res. 1989;49:2087-2090.
35. Menard S, Tagliabue E, Campiglio M, Pupa SM. Role of HER2 gene overexpression in breast carcinoma. J Cell Physiol. 2000;182:150-162.
36. Muss HB, Thor AD, Berry DA, et al. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med. 1994;330:1260-1266.
37. Menard S, Valagussa P, Pilotti S, et al. Response to cyclophosphamide, methotrexate, and fluorouracil in lymph node-positive breast cancer according to HER2 overexpression and other tumor biologic variables. J Clin Oncol. 2001;19:329-335.
38. Miles DW, Harris WH, Gillett CE, Smith P, Barnes DM. Effect of c-erbB(2) and estrogen receptor status on survival of women with primary breast cancer treated with adjuvant cyclophosphamide/methotrexate/fluorouracil. Int J Cancer. 1999;84:354-359.
39. Yu D, Liu B, Tan M, Li J, Wang SS, Hung MC. Overexpression of c-erbB-2/neu in breast cancer cells confers increased resistance to taxol via mdr-1-independent mechanisms. Oncogene. 1996;13:1359-1365.
40. Vogel CL, Cobleigh MA, Tripathy D, et al. First-line Herceptin monotherapy in metastatic breast cancer. Oncology. 2001;61(Suppl 2):37-42.
41. Pietras RJ, Fendly BM, Chazin VR, Pegram MD, Howell SB, Slamon DJ. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast cancer and ovarian cancer cells. Oncogene. 1994;9:1829-1838.
42. Jarvinen TA, Holli K, Kuukasjarvi T, Isola JJ. Predictive value of topoisomerase II alpha and other prognostic factors for epirubicin chemotherapy in advanced breast cancer. Br J Cancer. 1998;77:2267-2273.
43. Gibbs JB. Mechanism-based target identification and drug discovery in cancer research. Science. 2000;287:1969-1973.
44. Mielnicki LM, Asch HL, Asch BB. Genes, chromatin, and breast cancer: an epigenetic tale. J Mammary Gland Biol Neoplasia. 2001;6:169-182.
45. Yu D. Mechanisms of ErbB2-mediated paclitaxel resistance and trastuzumab-mediated paclitaxel sensitization in ErbB2-overexpressing breast cancers. Semin Oncol. 2001;28(5 Suppl 16):12-17.
46. Elledge RM, Allred DC. Prognostic and predictive value of p53 and p21 in breast cancer. Breast Cancer Res Treat. 1998;52:79-98.